)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Compass Therapeutics
Compass Therapeutics (CMPX) investor relations material
Compass Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary5 Mar, 2026
Executive summary
Lead asset tovecimig met the primary endpoint of overall response rate in the COMPANION-002 Phase 2/3 study for biliary tract cancer, with key secondary endpoint data (PFS and OS) expected in April 2026.
Expansion cohorts for CTX-8371 in TNBC, NSCLC, and Hodgkin lymphoma are enrolling, following strong responses in heavily pre-treated patients.
IND for CTX-10726 received FDA clearance; Phase 1 study to open enrollment in Q1 2026.
Expanded leadership team with new CMO, CCO, and promotion of CSO.
Cash and marketable securities of $209 million at year-end 2025, expected to fund operations into 2028.
Financial highlights
Net loss for 2025 was $66.5 million, or $0.42 per share, compared to $49.4 million, or $0.36 per share, in 2024.
R&D expenses rose to $56.0 million in 2025 from $42.3 million in 2024, mainly due to increased manufacturing costs for tovecimig and CTX-10726.
G&A expenses increased to $16.9 million in 2025 from $15.1 million in 2024, driven by pre-commercialization and advisory fees.
Cash and marketable securities increased to $209 million at year-end 2025 from $127 million at year-end 2024, supported by a $129 million public offering.
Outlook and guidance
PFS and OS data for tovecimig in biliary tract cancer expected in April 2026.
Phase 2 study of tovecimig in DLL4+ tumors to initiate mid-2026.
Initial data from CTX-8371 expansion cohorts and Phase 1 dose-escalation to be presented in Q2 2026.
Phase 1 study for CTX-10726 to open in Q1 2026, with clinical data expected in the second half of the year.
Phase 2 trial of CTX-471 in NCAM (CD56) expressing tumors to start mid-2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Compass Therapeutics earnings date
Q1 20266 May, 2026
Compass Therapeutics
Next Compass Therapeutics earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics primarily targeting oncology. The company’s research centers on the interaction between angiogenesis, the immune system, and tumor growth. Its pipeline includes novel therapeutic candidates designed to modulate key biological pathways to elicit an effective anti-tumor response. This includes strategies to influence the tumor microvasculature, activate immune cells, and overcome immunosuppressive mechanisms employed by tumors. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage